Shares of CVS Health (NYSE:CVS) traded marginally lower on Friday after rising from a low of $62.92 from past six trading sessions, where shares grew overall 6% to a high of $66.63. Today’s the stock ...

On Oct. 8, Keybanc analyst John Vinh maintained Micron Technology with an Overweight and lowered the price target from $145 ...

Fintel reports that on October 10, 2024, Barclays upgraded their outlook for CVS Health (NYSE:CVS) from Equal-Weight to ...

Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

Barclays analyst Andrew Mok CFA maintained a Buy rating on ... Mok CFA covers the Healthcare sector, focusing on stocks such as Centene, CVS Health, and Humana. The word on The Street in general, ...

The U.S. government announced quality ratings for 2025 Medicare health and prescription drug plans on Thursday, the first ...

Barclays upgraded CVS Health Inc (NYSE:CVS) on higher Pharmacy & Consumer Wellness (PCW) estimates as headwinds are offset by ...

First Solar ( FSLR) was the worst-performing stock in the S&P 500 when Jefferies lowered its price target, warning that ...

CVS Health, one of the biggest players in the battle to acquire physicians, is facing a possible split amid major financial struggles. In 2023, CVS Health spent $10.6 billion to acquire primary care ...

Analysts upgraded shares of the healthcare company to Overweight from Equal Weight and raised their price target to $82.

CVS Health (CVS) stock gained as Barclays upgraded the company, citing a compelling path to margin recovery in its Medicare ...

CVS Health (CVS – Research Report) received a Buy rating and an $82.00 price target from Barclays analyst Andrew Mok CFA today. The ...